Cambridge Consultants spin-out, Evonetix aims to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging field of synthetic biology.
By employing novel techniques the Chesterford Research Park company claims it can advance DNA synthesis to levels not previously seen.
The company was founded in 2015 with the support of Cambridge Consultants Ltd and the entrepreneur and co-founder of Amadeus Capital Partners, Hermann Hauser. It is developing a novel method of manufacturing DNA molecules, using a microchip-based array.
The resulting economies of scale mean that Evonetix’ technology will be more economical and flexible than the currently available methods, as well as being more comprehensive in its output. Given that DNA is the raw material for the fast-emerging and exciting field of synthetic biology, economical and flexible manufacture is critical.
Evonetix raised c$14 million in a 2018 Series A. The company, led by CEO Tim Brears, attracted $12.3m in January. The financing was co-led by DCVC (Data Collective) of Palo Alto and European-based Draper Esprit, and included the Morningside group, alongside existing investors Providence Investment Company (Jersey), Cambridge Consultants, and San Francisco duo Rising Tide Fund and Civilization. The company attracted an additional £1.3 million from Innovate UK in July.